[ET Net News Agency, 14 April 2020] Morgan Stanley raised its target price for Sino
Biopharmaceutical (01177) to HK$13 from HK$12.5 and maintained its "overweight" rating.
The research house said Sino Biopharm is a leader in the hepatitis market, with a solid
pipeline in other key therapeutic areas, such as oncology, respiratory and diabetes.
The oncology franchise may see robust growth driven by anlotinib and fast sales ramp-up
of near-commercialization I/O candidates and biosimilars.
Morgan sees considerable room for sales expansion of its blockbusters in the medium to
the long run and its robust pipeline products. (KL)